[go: up one dir, main page]

CL2016000466A1 - Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. - Google Patents

Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.

Info

Publication number
CL2016000466A1
CL2016000466A1 CL2016000466A CL2016000466A CL2016000466A1 CL 2016000466 A1 CL2016000466 A1 CL 2016000466A1 CL 2016000466 A CL2016000466 A CL 2016000466A CL 2016000466 A CL2016000466 A CL 2016000466A CL 2016000466 A1 CL2016000466 A1 CL 2016000466A1
Authority
CL
Chile
Prior art keywords
bmi
cancer
substituted
compounds derived
inhibitors
Prior art date
Application number
CL2016000466A
Other languages
English (en)
Inventor
Ramil Baiazitov
Wu Du
Young-Choon Moon
Steven D Paget
Hongyu Ren
Nadiya Sydorenko
Richard Gerald Wilde
Chang-Sun Lee
Original Assignee
Ptc Theraputics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Theraputics Inc filed Critical Ptc Theraputics Inc
Publication of CL2016000466A1 publication Critical patent/CL2016000466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE 2-AMINO PIRIDIMIDINA SUSTITUIDA, SUS SALES, HIDRATOS, SOLVATOS, QUELATOS, CLATRATO, POLIMORFO, ISOTOPÓLOGO, ESTEREOISÓMERO, RACEMATO, ENANTIÓMERO, DIASTEREÓMERO O TAUTÓMERO DE LOS MISMOS, QUE INHIBEN LA FUNCIÓN DE LA PROTEÍNA DEL SITIO DE INTEGRACIÓN 1 DEL VIRUS DE LA LEUCEMIA MURINA DE MOLONEY ESPECIFICO DE LOS LINFOCITOS B BMI-1 Y QUE REDUCEN EL NIVEL DE LA MISMA Y USO DE LOS COMPUESTOS PARA INHIBIR LA FUNCIÓN DE BMI-1 PARA TRATAR UN CÁNCER MEDIADO POR LA BMI-1
CL2016000466A 2013-08-30 2016-02-29 Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. CL2016000466A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361872091P 2013-08-30 2013-08-30
PCT/US2013/071216 WO2015030847A1 (en) 2013-08-30 2013-11-21 Substituted pyrimidine bmi-1 inhibitors

Publications (1)

Publication Number Publication Date
CL2016000466A1 true CL2016000466A1 (es) 2016-10-21

Family

ID=52587180

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000466A CL2016000466A1 (es) 2013-08-30 2016-02-29 Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.

Country Status (16)

Country Link
US (1) US10370371B2 (es)
EP (1) EP3039015B1 (es)
JP (2) JP6524094B2 (es)
KR (1) KR102232595B1 (es)
CN (1) CN105683166B (es)
AR (1) AR093580A1 (es)
AU (2) AU2013399092A1 (es)
CA (1) CA2922657C (es)
CL (1) CL2016000466A1 (es)
EA (1) EA034866B1 (es)
IL (1) IL244321B (es)
MX (1) MX370588B (es)
NZ (2) NZ748260A (es)
TW (1) TWI692477B (es)
WO (1) WO2015030847A1 (es)
ZA (1) ZA201601697B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ748260A (en) * 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10457669B2 (en) 2015-10-21 2019-10-29 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
AU2017209935B2 (en) 2016-01-22 2021-04-01 Janssen Pharmaceutica Nv New substituted cyanoindoline derivatives as NIK inhibitors
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
US20190119299A1 (en) 2016-06-30 2019-04-25 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
CN109641882B (zh) 2016-06-30 2022-10-28 杨森制药有限公司 作为nik抑制剂的杂芳族衍生物
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
MD3784664T2 (ro) 2018-04-26 2025-06-30 Pfizer Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
EP3813784B1 (en) * 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
CA3109386A1 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Use of 5-fluoro-2-(6-fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine in the treatment of pancreatic cancer
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
CN113710670A (zh) * 2019-02-28 2021-11-26 Ptc医疗公司 治疗多发性骨髓瘤的方法
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3966213A4 (en) 2019-05-05 2023-04-19 Qilu Regor Therapeutics Inc. CDK INHIBITORS
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
US20220267320A1 (en) 2019-07-24 2022-08-25 Merck Patent Gmbh 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
US12338248B2 (en) 2023-07-21 2025-06-24 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) 1973-09-20 1977-11-30 Delalande Sa
CA2120732C (en) 1991-10-07 2008-09-16 Barbara P. Wallner Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1996005177A1 (en) 1994-08-13 1996-02-22 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
IN188411B (es) * 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) * 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
JP2003523942A (ja) * 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE60039059D1 (de) 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
US6608072B1 (en) 1999-10-27 2003-08-19 Novartis Ag Thiazole compounds and their pharmaceutical use
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
NZ521068A (en) 2000-03-29 2005-04-29 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
JP4105947B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なトリアゾール化合物
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1423388B1 (en) * 2001-02-20 2008-12-03 AstraZeneca AB 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
JP4342937B2 (ja) * 2001-07-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン
US7109204B2 (en) * 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4552650B2 (ja) 2002-06-28 2010-09-29 日本新薬株式会社 アミド誘導体及び医薬
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7582630B2 (en) 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
NZ549880A (en) 2004-03-30 2010-04-30 Vertex Pharma Azaindoles useful as inhibitors of JAK and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
JP2008533042A (ja) 2005-03-10 2008-08-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン 過剰増殖性疾患の処置のためのピリミジン誘導体
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
EP2074113A1 (en) 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
CN101679432B (zh) 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
BRPI0720635A2 (pt) * 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) * 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MY152948A (en) * 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
PL2231636T3 (pl) * 2007-12-07 2012-04-30 Novartis Ag Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin
DE102008005493A1 (de) * 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
EP2306836B1 (en) * 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
US8618099B2 (en) 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
AU2010214440A1 (en) 2009-02-12 2011-09-01 Astellas Pharma Inc. Hetero ring derivative
AR075974A1 (es) 2009-03-27 2011-05-11 Pathway Therapeutics Ltd Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
EP2435435B1 (en) 2009-05-27 2014-01-29 AbbVie Inc. Pyrimidine inhibitors of kinase activity
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
SI3141252T1 (sl) 2009-06-17 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov influence
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
JP5415176B2 (ja) 2009-08-06 2014-02-12 株式会社マキタ スイッチ
CA2786800C (en) 2010-01-12 2018-02-27 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EA023931B1 (ru) 2010-08-10 2016-07-29 Астеллас Фарма Инк. Гетероциклическое соединение
SI2616465T1 (sl) 2010-09-13 2016-02-29 Novartis Ag Triazin-oksadiazoli
WO2012050884A2 (en) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
BR112013019942B1 (pt) 2011-02-25 2022-01-11 Yuhan Corporation Uso de composto ou de seu sal farmaceuticamente aceitável, composição farmacêutica, compostos ou seus sais farmaceuticamente aceitáveis e respectivos processos de preparação
AU2012280725B2 (en) 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
WO2014081906A2 (en) 2012-11-21 2014-05-30 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
NZ748260A (en) * 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors

Also Published As

Publication number Publication date
US20160214978A1 (en) 2016-07-28
EA034866B1 (ru) 2020-03-31
EP3039015A1 (en) 2016-07-06
EP3039015B1 (en) 2019-10-30
CN105683166B (zh) 2020-06-16
BR112016004511A2 (pt) 2017-09-12
AU2018271277A1 (en) 2018-12-20
WO2015030847A1 (en) 2015-03-05
KR20160048920A (ko) 2016-05-04
TW201512188A (zh) 2015-04-01
ZA201601697B (en) 2021-07-28
NZ748260A (en) 2020-01-31
HK1226057A1 (zh) 2017-09-22
AR093580A1 (es) 2015-06-10
JP6728321B2 (ja) 2020-07-22
BR112016004511A8 (pt) 2021-11-30
AU2018271277B2 (en) 2020-07-16
US10370371B2 (en) 2019-08-06
MX2016002642A (es) 2016-08-12
NZ718055A (en) 2020-01-31
IL244321A0 (en) 2016-04-21
IL244321B (en) 2020-07-30
CA2922657C (en) 2022-04-12
MX370588B (es) 2019-12-16
KR102232595B1 (ko) 2021-03-26
EA201690502A1 (ru) 2016-08-31
TWI692477B (zh) 2020-05-01
CA2922657A1 (en) 2015-03-05
CN105683166A (zh) 2016-06-15
JP2016529292A (ja) 2016-09-23
AU2013399092A1 (en) 2016-03-17
JP2019059778A (ja) 2019-04-18
JP6524094B2 (ja) 2019-06-05
EP3039015A4 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
CL2016000466A1 (es) Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2016013182A (es) Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
MX389825B (es) Compuestos y composiciones para tratar trastornos hematologicos.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
ECSP16067303A (es) Heteroarilos y usos de estos
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
AR103680A1 (es) Inhibidores selectivos de bace1
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2014000887A1 (es) Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas